Advertisement

Advertisement
Prostate Cancer

Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial

As reported at the ASCO20 Virtual Scientific Program and in The New England Journal of Medicine by Shore et al, the phase III...

Lung Cancer
Bladder Cancer
Colorectal Cancer
Immunotherapy

Plenary Research From the ASCO20 Virtual Scientific Program: Part 1

This week on The ASCO Post Podcast, we’ll be hearing from the authors of three late-breaking abstracts presented...

 

Prostate Cancer

Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer

Initial results of the randomized phase II TheraP trial show that therapy directed to prostate-specific membrane antigen...


Advertisement
Immunotherapy

Does Treatment With Immune Checkpoint Inhibitors Cause Flare-ups in Patients With Preexisting IBD or Microscopic Colitis?

In a retrospective analysis reported in JCO Oncology Practice, Grover et al found that enterocolitis flares occurred in approximately...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




COVID-19
Global Cancer Care
Skin Cancer

Paolo A. Ascierto, MD, on Cancer Treatment During the COVID-19 Pandemic: The View From Southern Italy

Hepatobiliary Cancer

Ivosidenib for IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma

As reported by Ghassan K. Abou-Alfa, MD, and colleagues in The Lancet Oncology, the phase III ClarIDHy trial has shown that the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib improved progression-free survival vs placebo in patients with advanced IDH1-mutant chemotherapy-refractory...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland

Gynecologic Cancers

Cediranib/Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however,...

Solid Tumors
Genomics/Genetics

RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions

The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109). “This trial shows...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Helping Ease Oncology Patients’ Fears of Contracting COVID-19

Issues in Oncology

Exposure to Fine Particulate Matter May Increase Mortality Among Pediatric and AYA Patients With Certain Cancers

An analysis of nearly 16,000 pediatric and adolescent/young adult (AYA) patients with cancer in Utah revealed that exposure to fine particulate matter was associated with increased mortality at 5 and 10 years after diagnosis of certain cancers, according to a study published by Ou et al in Cancer...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...